0.95
price up icon0.00%   0.00
after-market Handel nachbörslich: .95
loading
Schlusskurs vom Vortag:
$0.95
Offen:
$0.95
24-Stunden-Volumen:
27,101
Relative Volume:
0.33
Marktkapitalisierung:
$56.38M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-112.67M
KGV:
-0.4502
EPS:
-2.11
Netto-Cashflow:
$-79.26M
1W Leistung:
-3.16%
1M Leistung:
-4.31%
6M Leistung:
-6.86%
1J Leistung:
+3.26%
1-Tages-Spanne:
Value
$0.935
$0.9631
1-Wochen-Bereich:
Value
$0.92
$1.00
52-Wochen-Spanne:
Value
$0.69
$1.60

Kronos Bio Inc Stock (KRON) Company Profile

Name
Firmenname
Kronos Bio Inc
Name
Telefon
(650) 781-5200
Name
Adresse
1300 S. EL CAMINO REAL, SAN MATEO
Name
Mitarbeiter
58
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-11
Name
Neueste SEC-Einreichungen
Name
KRON's Discussions on Twitter

Kronos Bio Inc Stock (KRON) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2022-09-14 Eingeleitet Berenberg Buy
2021-10-20 Fortgesetzt Cowen Outperform
2021-06-24 Eingeleitet H.C. Wainwright Buy
2020-11-03 Eingeleitet Cowen Outperform
2020-11-03 Eingeleitet Goldman Buy
2020-11-03 Eingeleitet Jefferies Buy
2020-11-03 Eingeleitet Piper Sandler Overweight
Alle ansehen

Kronos Bio Inc Aktie (KRON) Neueste Nachrichten

pulisher
09:11 AM

Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma - The Manila Times

09:11 AM
pulisher
Nov 04, 2024

Non-Hodgkin’s Lymphoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail

Nov 04, 2024
pulisher
Nov 04, 2024

TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail

Nov 04, 2024
pulisher
Nov 01, 2024

Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace

Nov 01, 2024
pulisher
Oct 30, 2024

Non-Hodgkin Lymphoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail

Oct 30, 2024
pulisher
Oct 29, 2024

Nio Inc ADR (NIO-N) QuotePress Release - The Globe and Mail

Oct 29, 2024
pulisher
Oct 29, 2024

Phillips-Van Heusen Corp (PVH-N) QuotePress Release - The Globe and Mail

Oct 29, 2024
pulisher
Oct 25, 2024

After Plunging -23.49% in 4 Weeks, Here's Why the Trend Might Reverse for Kronos Bio (KRON) - MSN

Oct 25, 2024
pulisher
Oct 23, 2024

Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors - The Manila Times

Oct 23, 2024
pulisher
Oct 23, 2024

Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium - GlobeNewswire

Oct 23, 2024
pulisher
Oct 23, 2024

Taylor Morrison Home Corp (TMHC-N) QuotePress Release - The Globe and Mail

Oct 23, 2024
pulisher
Oct 09, 2024

Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors - The Manila Times

Oct 09, 2024
pulisher
Oct 09, 2024

Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium - GlobeNewswire

Oct 09, 2024
pulisher
Oct 08, 2024

Kronos Bio's (KRON) "Overweight" Rating Reaffirmed at Piper Sandler - MarketBeat

Oct 08, 2024
pulisher
Oct 08, 2024

Kronos Bio nominates KAT inhibitor as development candidate for Sjögren’s disease - BioWorld Online

Oct 08, 2024
pulisher
Oct 08, 2024

Piper Sandler maintains Overweight rating on Kronos Bio shares - Investing.com

Oct 08, 2024
pulisher
Oct 08, 2024

Kronos Bio nominates KB-7898 for autoimmune disease treatment - Investing.com

Oct 08, 2024
pulisher
Oct 07, 2024

Kronos Bio nominates KB-7898 for autoimmune disease treatment By Investing.com - Investing.com South Africa

Oct 07, 2024
pulisher
Oct 07, 2024

Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren's Disease - The Manila Times

Oct 07, 2024
pulisher
Oct 07, 2024

Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren’s Disease - GlobeNewswire

Oct 07, 2024
pulisher
Oct 01, 2024

Plexium Announces Appointment of Jorge F. DiMartino, M.D., Ph.D. as Chief Medical Officer - PR Newswire

Oct 01, 2024
pulisher
Sep 29, 2024

Kronos Bio, Inc. (NASDAQ:KRON) Position Increased by Forefront Analytics LLC - Defense World

Sep 29, 2024
pulisher
Sep 25, 2024

Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy - StockTitan

Sep 25, 2024
pulisher
Sep 25, 2024

Kronos Bio to Present Data at ACR Convergence 2024 to - GlobeNewswire

Sep 25, 2024
pulisher
Sep 23, 2024

Keros Therapeutics (NASDAQ:KROS) Shares Gap Up to $55.80 - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

Avoro Capital Advisors LLC Reduces Position in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

Integral Health Asset Management LLC Acquires 45,000 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

How the (KROS) price action is used to our Advantage - Stock Traders Daily

Sep 23, 2024
pulisher
Sep 23, 2024

How does Keros Therapeutics Inc (KROS) change from a tortoise to a hare? - SETE News

Sep 23, 2024
pulisher
Sep 23, 2024

Kronos Bio highlights istisociclib data at Ovarian Cancer Research Symposium - TipRanks

Sep 23, 2024
pulisher
Sep 23, 2024

71,428 Shares in Korro Bio, Inc. (NASDAQ:KRRO) Acquired by Tri Locum Partners LP - MarketBeat

Sep 23, 2024
pulisher
Sep 23, 2024

Kronos Bio Highlights Data at AACR Ovarian Cancer Research - GlobeNewswire

Sep 23, 2024
pulisher
Sep 23, 2024

Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian Cancer - StockTitan

Sep 23, 2024
pulisher
Sep 23, 2024

Keros Therapeutics (NASDAQ:KROS) Receives New Coverage from Analysts at Guggenheim - MarketBeat

Sep 23, 2024
pulisher
Sep 23, 2024

Guggenheim starts Keros Therapeutics with 'buy' on lung disorder drug potential - XM

Sep 23, 2024
pulisher
Sep 23, 2024

Guggenheim bullish on Keros Therapeutics stock driven by PAH treatment prospects - Investing.com Australia

Sep 23, 2024
pulisher
Sep 22, 2024

Gogo Inc. (NASDAQ:GOGO) Shares Sold by Yarra Square Partners LP - Defense World

Sep 22, 2024
pulisher
Sep 22, 2024

American Century Companies Inc. Has $13.63 Million Stock Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World

Sep 22, 2024
pulisher
Sep 21, 2024

Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Bought by Rhumbline Advisers - Defense World

Sep 21, 2024
pulisher
Sep 19, 2024

Pharmacosmos after major acquisition: “The next six months are about integrating G1 well” - MedWatch

Sep 19, 2024
pulisher
Sep 18, 2024

Understanding CRON stock ratios for better investment decisions - US Post News

Sep 18, 2024
pulisher
Sep 18, 2024

DekaBank Deutsche Girozentrale Has $4.25 Million Holdings in Dollar Tree, Inc. (NASDAQ:DLTR) - Defense World

Sep 18, 2024
pulisher
Sep 18, 2024

Kronos Bio, Inc. (NASDAQ:KRON) Short Interest Update - MarketBeat

Sep 18, 2024
pulisher
Sep 16, 2024

ABIVAX Société Anonyme (NASDAQ:ABVX) Sees Large Growth in Short Interest - Defense World

Sep 16, 2024
pulisher
Sep 10, 2024

After Plunging -5.53% in 4 Weeks, Here's Why the Trend Might Reverse for Kronos Bio (KRON) - Yahoo Finance

Sep 10, 2024
pulisher
Sep 03, 2024

Kronos Bio Announces Participation in Medical and Investor Conferences in September - Marketscreener.com

Sep 03, 2024
pulisher
Sep 02, 2024

The Psychology of Kronos Bio Inc Inc. (KRON) Price Performance: Understanding Market Sentiment - The InvestChronicle

Sep 02, 2024
pulisher
Sep 02, 2024

Kronos Bio Inc (KRON) rating initates by Berenberg - Knox Daily

Sep 02, 2024

Finanzdaten der Kronos Bio Inc-Aktie (KRON)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Kapitalisierung:     |  Volumen (24h):